Language selection

Government of Canada / Gouvernement du Canada

Search

References: Modelling the Incidence and Prevalence of Hepatitis C Infection and its Sequelae in Canada, 2007

References

  1. Remis RS, Hogg RS, Krahn MD, et al. Estimating the number of blood transfusion recipients infected by hepatitis C virus in Canada, 1960-85 and 1990-92. 49 pp. [Under contract for Health Canada] June 1998.
  2. Remis RS. Characterizing the epidemiology of hepatitis C infection in Canada to 2002. 49 pp. [Under contract for Public Health Agency of Canada] September 2003. http://www.phac-aspc.gc.ca/hepc/pubs/hepc2002/index-eng.php
  3. Statistics Canada. Population projections for Canada, provinces and territories 2005-2031. Catalogue no: 91-520-XWE. http://www.statcan.gc.ca/bsolc/olc-cel/olc-cel?lang=eng&catno=91-520-X.
  4. Remis RS, Strathdee SA, Millson M, et al. Consortium to characterize injection drug users in Montreal, Toronto and Vancouver, Canada. Contract for Health Canada, March 1998.
  5. Archibald CP, Jayaraman GC, Major C, et al. Estimating the size of hard-to-reach populations: A novel method using HIV testing data compared to other methods. AIDS 2001; 15 (Supp3):S141-S48.
  6. Single E. A socio-demographic profile of drug users in Canada. HIV/AIDS Prevention and Community Action Program, Health Canada, 2000.
  7. Darby SC, Ewart DW, Glangrande PLF et al. Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425-1431.
  8. Darby SC, Ewart DW, Glangrande PLF et al. Mortality before and after HIV infection in the complete UK population of haemophilics. Nature 1995; 377: 79-82.
  9. Jones PK, Ratnoff OD. The changing prognosis of classic haemophilia (factor VIII "deficiency"). Ann Intern Med 1991; 114(8):641-648.
  10. Zou S, Zhang J, Tepper M, et al. Enhanced surveilllance of hepatitis B and C in four health regions in Canada, 1998-99. Can J Infect Dis 2001; 12:357-363.
  11. Wu HX, Wu J, Wong T, et al. Enhanced surveillance of newly acquired hepatitis C virus infection in Canada, 1998 to 2004. Scand J Infect Dis 2006; 39(6-7):482-489.
  12. Chaudhary RK, Mo T. Antibody to hepatitis C virus in risk groups in Canada. Can Dis Wkly Rep 1990; 16:23-25.
  13. Anand CM, Fonseca K, Walle RP, et al. Antibody to hepatitis C virus in selected groups of a Canadian population. Int J Epidemiol 1992; 21:142-145.
  14. Louie M, Low DE, Feinma V, et al. Prevalence of bloodborne infective agents among people admitted to a Canadian Hospital. Can Med Assoc J 1992; 146:1331-1334.
  15. Manuel DG, Johnson I, Fearon M, et al. The prevalence of hepatitis C in a community-based population, Ontario, 1996. Commun Dis Rep 1999; 25:193-199.
  16. Joly JR, Alary M, Delage G, et al. HCV infection in outpatients at sentinel hospitals in Quebec. Personal communication, May 1998.
  17. Chaudhary RK, Rossier E. Prevalence of hepatitis C virus antibodies in renal transplant patients. Can Dis Wkly Rep 1991; 17:53-54.
  18. Armstrong S, Gangam N, Chipman ML, et al. The prevalence of positive hepatitis B, hepatitis C and HIV serology in cornea donors prescreened by medical and social history in Ontario, Canada. Cornea 1997; 16:512-516.
  19. Delage G, Infante-Rivard C, Chiavetta JA, et al. Risk factors for acquisition of hepatitis C virus infection in blood donors: Results of a case-control study. Gastroenterology 1999; 116:893-899.
  20. Lior L, Stratton E, Archibald CP, et al. Eastern Region Project: Seroprevalence of HIV, HBV, and HCV viruses and high risk behaviours among IDU and sexual partners of IDU. Slide presentation, Health Canada.
  21. Siushansian J, Vooght M, Archibald CP, et al. The Prince Albert Seroprevalence Study. Slide presentation, Health Canada.
  22. Ford PM, White C, Kaufmann H, et al. Seroprevalence of hepatitis C in a Canadian federal penitentiary for women. Can Commun Dis Rep 1995; 21:132-134.
  23. Pearson M, Mistry PS, Ford PM. Voluntary screening for hepatitis C in a Canadian federal penitentiary for men. Can Commun Dis Rep 1995; 21:134-136.
  24. Ford PM, White C, Kaufmann H, et al. Voluntary anonymous linked study of the prevalence of HIV infection and hepatitis C among inmates in a Canadian federal penitentiary for women. Can Med Assoc J 1995; 153:1605-1609.
  25. Ford PM, Pearson M, Sankar-Mistry P, et al. HIV, hepatitis C and risk behaviour in a Canadian medium-security federal penitentiary. Queen's University HIV Prison Study Group. QJM 2000; 93:113-119.
  26. Prefontaine RG, Chaudhary RK. Seroepidemiologic study of hepatitis B and C viruses in federal correctional institutions in British Columbia. Can Dis Wkly Rep 1990; 16:265-266.
  27. Calzavara L, Burchell A, Myers T, et al. Prevalence and risk factors for HIV and hepatitis C infection in Ontario's jails and detention centres, 2003-04. Technical report. Department of Public Health Sciences, University of Toronto, March 31, 2006.
  28. Landry S, Alary M, Godin G, et al. Prevalence of HIV and hepatitis C infections in inmates of Quebec provincial prisons. Can J Infect Diseases 2004; 15 (Supp A):50A.
  29. Smith J. Viral hepatitis in Canadian federal penitentiaries. Focus on Infectious Diseases, Correctional Service Canada Winter 2005; 3:1.
  30. Infectious Diseases Prevention and Control in Canadian federal penitentiaries, 2000-01. Correctional Service Canada/Public Health Agency of Canada, 2003.
  31. Skoretz S, Zaniewski G, Goedhuis NJ. Hepatitis C virus transmission in the prison/inmate population. Can Commun Dis Rep 2004 Aug 15; 30(16):141-148.
  32. Public Health Agency of Canada. Hepatitis C virus infection among street youth (1999-2005). Community Acquired Infections Division, Centre for Communicable Disease and Infection Control, Public Health Agency of Canada, 2008. http://www.phac-aspc.gc.ca/sti-its-surv-epi/epi/hepc-eng.php
  33. Roy E, Haley N, Leclerc P, et al. Risk factors for hepatitis C virus infection among street youths. Can Med Assoc J 2001; 165:557-560.
  34. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997 Jul; 11(8):F59-65.
  35. Patrick DM, Tyndall MW, Cornelisse PG, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Can Med Assoc J 2001; 165:889-895.
  36. Millson M, Leonard L, Remis RS, et al. Bloodborne infections among injection drug users in Ontario. Department of Public Health Sciences, University of Toronto, January 2005.
  37. Public Health Agency of Canada. I-Track: Enhanced surveillance of risk behaviours among people who inject drugs. Phase I Report, August 2006. Surveillance and Risk Assessment Division, Centre for Communicable Disease and Infection Control, Public Health Agency of Canada, 2006. http://www.phac-aspc.gc.ca/i-track/sr-re-1/pdf/itrack06_e.pdf 
  38. Roy E, Alary M, Morissette C, et al. High hepatitis C prevalence and incidence among Canadian intravenous drug users. Int J STD & AIDS 2007; 18:23-27
  39. Institut national de santé du Québec. Surveillance des maladies infectieuses chez les utilisateurs de drogue par injection. Epidémiologie du VIH de 1995 à 2007 – Epidémiologie du VHC de 2003 à 2007. http://www.inspq.qc.ca/pdf/publications/855_RapSurvUDI.pdf 
  40. Heath KV, Cornelisse PG, Strathdee SA,et al HIV-associated risk factors among young Canadian Aboriginal and non-Aboriginal men who have sex with men. Int J STD AIDS 1999 Sep; 10(9): 582-587.
  41. Minuk GY, Uhanova J. Viral hepatitis in the Canadian and First Nations populations. Can J Gastroenterol 2003; 17(12):707-712.
  42. Cedar Project Partnership, Mehrabadi A, Paterson K, et al. Gender differences in HIV and hepatitis C related vulnerabilities among aboriginal young people who use street drugs in two Canadian cities. Women's Health 2008 48(3):235-60.
  43. Moses S, Mestery K, Kaita KDE, et al. Viral hepatitis in a Canadian street involved population. Can J Public Health 2002; 93:123-128.
  44. Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90:1562-1569.
  45. Muir AJ. The natural history of hepatitis C viral infection. Semin Gastrointest Dis 2000; 11: 54-61.
  46. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(5 Suppl 1): S35-46.
  47. Hyams KC, Riddle J, Rubertone M, et al. Prevalence and incidence of hepatitis C virus infection in the US military: A seroepidemiologic survey of 21,000 troops. Am J Epidemiol 2001; 153:764-770.
  48. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33:455-463.
  49. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127:855-865.
  50. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34(4 Pt 1): 809-816.
  51. Salomon JA, Weinstein MC, Hammitt JK, et al. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002; 156:761-773.
  52. Krahn M, Wang P, Yi Q, et al. Estimating the prognosis of Canadians infected with the hepatitis C virus through the blood supply, 1986-1990: First revision of prognostic model incorporating data from the compensation claimant cohort, Toronto, Canada, June 3, 2002.
  53. Krahn M, Wong JB, Heathcote J, et al. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making 2004; 24(1):20-29.
  54. elSaadany S, Tepper M, Mao Y, et al. An epidemiologic study of hepatocellular carcinoma in Canada. Can J Public Health 2002; 93:443-446.
  55. Pohani G, Zou S, Tepper M. Trends of hepatitis B and hepatitis C mortality in Canada, 1979-1997. Can J Public Health 2001; 92:250-254.
  56. Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol 2000; 14:575-578.
  57. Lamothe F, Vincelette J, Bruneau J, et al. Prevalence, seroconversion rates and risk factors for hepatitis B core, hepatitis C and HIV antibodies among intravenous drug users (IDU) of the Saint-Luc Cohort (Abstract 221). 6th Annual Canadian Conference on HIV/AIDS Research, May 1997 in Canadian Journal of Infectious Diseases 1997; 8(suppl A):28A.
  58. Remis RS, Zou S. Epidemiology of hepatitis C in Canada. Invited address, First Canadian Hepatitis C Conference, Montreal, Quebec, May 2, 2001.
  59. Ontario HIV Epidemiologic Monitoring Unit.
  60. J Smith. Health Services Branch. Corrections Services Canada. Personal communication, March 2009.
  61. Correctional Services Canada; Infectious Disease Surveillance in Canadian Federal Penitentiaries 2005-2006. Preliminary Unpublished Data (used with permission).

Page details

2017-06-20